Author

C. A. Freije

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 2 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Research Focus:variant effect prediction· 1 Organism:virus· 1

Frequent Co-Authors

A. C. Stanton· 1 shared A. F. Stenzel· 1 shared A. Peace· 1 shared A. Pinharanda· 1 shared A. W. Ashbrook· 1 shared B. A. Petros· 1 shared B. L. MacInnis· 1 shared B. M. Shaw· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. C. Stanton

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist

J. Le Pen, G. Paniccia, V. Kinast, M. Moncada-Velez, A. W. Ashbrook, M. Bauer, H.- H. Hoffmann, A. Pinharanda, I. Ricardo-Lax, A. F. Stenzel, E. A. Rosado-Olivieri, K. H. Dinnon, W. C. Doyle, C. A. Freije, S.-H. Hong, , C. M. Rice

The paper identifies PLSCR1 as a host factor restricting SARS-CoV-2 entry, which recent variants have evolved to bypass, through a CRISPR screen and integration of genetic studies.

bioRxiv · Feb 16, 2024Immunology

Integrated sample inactivation, amplification, and Cas13-based detection of SARS-CoV-2

J. Arizti-Sanz, C. A. Freije, A. C. Stanton, C. K. Boehm, B. A. Petros, S. Siddiqui, B. M. Shaw, G. Adams, T.-S. F. Kosoko-Thoroddsen, M. E. Kemball, R. Gross, L. Wronka, K. Caviness, L. E. Hensley, N. H. Bergman, , C. Myhrvold

This paper develops SHINE, a diagnostic tool for SARS-CoV-2 detection with 90% sensitivity and 100% specificity, reducing contamination risk and enabling use outside clinical settings.

bioRxiv · May 28, 2020 · PreprintBioengineering